Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients.

ABSTRACT: Objectives. To evaluate the effect of levothyroxine (LT₄) replacement therapy on nonalcoholic fatty liver disease (NAFLD) in subclinical hypothyroidism (SCH) patients. Methods. This study was a post hoc analysis of a randomized controlled trial and involved 33 significant and 330 mild SCH patients. All of the significant SCH patients received LT₄ supplement. The mild SCH patients were grouped as LT₄ treated or not. After 15 months of follow-up, prevalence of NAFLD in each group was reevaluated. Subgroup analysis was conducted in mild SCH patients with dyslipidemia. Results. After treatment with LT₄, the prevalence of NAFLD in significant SCH patients reduced from 48.5% to 24.2% (p = 0.041). In mild SCH patients, preval

SUBMITTER: Liu L 

PROVIDER: S-EPMC5394912 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature